Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics

NEW YORK; Nov. 9, 2021 – Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations. 

Comments

Popular posts from this blog

Add Custom Field in Output of Standard Report of ME2N

UK to Receive Egyptian LNG Cargo

HANA Housekeeping using HANACleaner